NASDAQ · IINN
Inspira Technologies OXY B.H.N. Ltd.
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
Loading market information…
NASDAQ · COSM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cosmos Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cosmos Health Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cosmos Health Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | -$0.03-4.67% vs estimate | $13.71M-11.53% vs estimate |
|---|
| Q1 2025 | Apr 15, 2025 | -$0.50-455.56% vs estimate | $14.22M-1.9% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.45-309.09% vs estimate | $12.41M-11.35% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$3.86-$0.09 (-2.28%)
SCYNEXIS, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.68% below the high.
$1.36-$0.06 (-3.9%)
Femasys Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.9% below the high.
$3.52+$0.19 (+5.71%)
Passage Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.4% below the high.
$1.01-$0.05 (-4.72%)
Lisata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.08% below the high.
$1.19+$0.05 (+4.39%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
$1.04-$0.04 (-3.26%)
NuCana plc’s quoted price sits in the lower half of its reported 52-week range, 77.14% below the high.
$0.11+$0.01 (+10.0%)
CASI Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.86% below the high.
